Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Neviani

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Blood|August 9, 2013
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignanciesJoshua J Oaks, Ramasamy Santhanam, Christopher J Walker, et al.
The Journal of Clinical Investigation|March 5, 2014
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcomeHouda Alachkar, Ramasamy Santhanam, Kati Maharry, et al.
Nature Communications|November 29, 2017
Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAsIvan Vannini, Petra M Wise, Kishore B Challagundla, et al.
Nature Communications|January 10, 2018
Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAsIvan Vannini, Petra M Wise, Kishore B Challagundla, et al.
Blood Cancer Discovery|September 25, 2020
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating FunctionsGiovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, et al.
The Journal of Clinical Investigation|September 4, 2013
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cellsPaolo Neviani, Jason G Harb, Joshua J Oaks, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Blood|August 9, 2013
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignanciesJoshua J Oaks, Ramasamy Santhanam, Christopher J Walker, et al.
The Journal of Clinical Investigation|March 5, 2014
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcomeHouda Alachkar, Ramasamy Santhanam, Kati Maharry, et al.
Nature Communications|November 29, 2017
Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAsIvan Vannini, Petra M Wise, Kishore B Challagundla, et al.
Nature Communications|January 10, 2018
Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAsIvan Vannini, Petra M Wise, Kishore B Challagundla, et al.
Blood Cancer Discovery|September 25, 2020
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating FunctionsGiovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, et al.
The Journal of Clinical Investigation|September 4, 2013
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cellsPaolo Neviani, Jason G Harb, Joshua J Oaks, et al.
Pageof 5